The Effects Of Selective Serotonin Reuptake Inhibitor (Sertraline) On Premenstrual Tension Syndrome
Obstetrics Gynecology and Reproductive Sciences · 2018
DOI: 10.31579/2578-8965/006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obstetrics Gynecology and Reproductive Sciences, 2018. Verfasst von Mohamed MK.
Abstract (Originalsprache)
Background
Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome (PMS).
Aim
To examine the effect of selective serotonin reuptake inhibitor (sertraline) on electroencephalographic (EEG) patterns, and clinical manifestations in females with PMS. Materials and Methods This prospective observational study was conducted on 200 females. Patients will be subdivided into two groups: Group A (control): includes 80 normal females and Group B consists of 120 patients with PMS. Patients with PMS were given sertraline 50 mg/day orally, initiated 14 days before the expected onset of menses and discontinued the day menses began.
Results
We found that sertraline has no substantial effects on EEG findings, simply it relieved the clinical symptoms.
Conclusions
We recommend use of SSRIs in the treatment of PMS.
Zitieren
APA
MK, M. (2018). The Effects Of Selective Serotonin Reuptake Inhibitor (Sertraline) On Premenstrual Tension Syndrome. Obstetrics Gynecology and Reproductive Sciences. https://doi.org/10.31579/2578-8965/006
Vancouver
MK M. The Effects Of Selective Serotonin Reuptake Inhibitor (Sertraline) On Premenstrual Tension Syndrome. Obstetrics Gynecology and Reproductive Sciences. 2018. doi:10.31579/2578-8965/006
BibTeX
@article{MK2018,
author = {MK, Mohamed},
title = {The Effects Of Selective Serotonin Reuptake Inhibitor (Sertraline) On Premenstrual Tension Syndrome},
journal = {Obstetrics Gynecology and Reproductive Sciences},
year = {2018},
doi = {10.31579/2578-8965/006}
}
EUVIMED